Xeris Biopharma Holdings, Inc. (XERS)

1.7600 -0.0200 (-1.12%) At close: 04:00PM EDT

Xeris Biopharma Holdings, Inc.

180 North LaSalle Street
Suite 1600
Chicago, IL 60601
United States
844 445 5704
https://www.xerispharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 377

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Paul R. Edick	Chairman & CEO	1.12M	N/A	1956
Mr. John P. Shannon	President & COO	827.72k	N/A	1962
Ms. Beth P. Hecht J.D.	Chief Legal Officer & Corporate Secretary	638.31k	N/A	1964
Mr. Steven M. Pieper	Chief Financial Officer	N/A	N/A	1977
Ms. Allison Wey	Senior Vice President of Investor Relations & Corporate Communications	N/A	N/A	N/A
Dr. Kenneth E. Johnson Pharm. D., Pharm.D.	Senior VP of Global Development & Medical Affairs	N/A	N/A	1963
Mr. Kevin McCulloch	Chief Commercial Officer	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

Corporate governance

Xeris Biopharma Holdings, Inc.’s ISS governance QualityScore as of 1 April 2024 is 10. The pillar scores are Audit: 8; Board: 9; Shareholder rights: 8; Compensation: 10.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.